NCE-1 Intelligence & Market Opportunity

Rhapsido

Remibrutinib

Immunomodulators

Oral Tablet

Rhapsido is an oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). By blocking mast cell activation and histamine release, it effectively reduces hives and itch in patients unresponsive to antihistamines.

Approval Date

30-Sep-25

NCE-1 Date

30-Sep-29

NCE Date

30-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

229.11%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

346

2027

843

2028

1,525

2029

2,229

2030

2,884

2031

3,520

2032

4,126

Molecule profile

Details & specifications

Molecule

Remibrutinib

Innovator

NOVARTIS PHARMS CORP

Dosage Form

Oral Tablet

Strength

25 mg

Therapeutic Category

Immunomodulators

Usage

To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets